Literature DB >> 15269493

Fenofibrate-induced myopathy.

Bhaskar Ghosh1, S Sengupta, B Bhattacharjee, A Majumder, S B Sarkar.   

Abstract

Fenofibrate induced myopathy is a rare adverse event. We present a case of muscle pain and quadriparesis following administration of 200mg of fenofibrate for 35 days. Patient gradually improved after stopping the drug. As per our knowledge, this is probably the first case report of fenofibrate induced myopathy from India.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15269493

Source DB:  PubMed          Journal:  Neurol India        ISSN： 0028-3886            Impact factor:   2.117


  7 in total

Review 1.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review.

Authors:  Ramazan Danis; Sami Akbulut; Sehmus Ozmen; Senay Arikan
Journal:  Case Rep Med       Date:  2010-07-25

3.  New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.

Authors:  A Liu; Y Chen; Z Yang; Y Feng; W Rui; W Luo; Y Liu; F J Gonzalez; R Dai
Journal:  Xenobiotica       Date:  2009-04       Impact factor: 1.908

4.  Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.

Authors:  Aiming Liu; Andrew D Patterson; Zongtao Yang; Xinying Zhang; Wei Liu; Fayang Qiu; He Sun; Kristopher W Krausz; Jeffrey R Idle; Frank J Gonzalez; Renke Dai
Journal:  Drug Metab Dispos       Date:  2009-02-27       Impact factor: 3.922

Review 5.  Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.

Authors:  Dawei Wang; Yanqiu Wang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

6.  Ascorbic Acid Significantly Decreases Creatine Kinase Plasma Levels in an Animal Model of Statin/Fibrate-Induced Myopathy.

Authors:  Mohsen Zabihi; Fatemeh Askarian; Seyedhossein Hekmatimoghaddam; Mohammadreza Rashidi Nooshabadi; Mohammad Sajjad Zabihi; Seyed Ruhollah Mousavinasab
Journal:  Adv Pharmacol Pharm Sci       Date:  2021-12-29

7.  Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells.

Authors:  Yat Hei Leung; Jacques Turgeon; Veronique Michaud
Journal:  Pharmaceutics       Date:  2017-10-10       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.